SubHero Banner

Olumiant® (baricitinib) – Emergency use authorization approval

November 20, 2020 - The FDA announced the emergency use authorization (EUA) of Eli Lilly’s Olumiant (baricitinib), in combination with Veklury® (remdesivir), for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Download PDF